ABSTRACT
3 beta-Hydroxycholest-5-en-7-one (I; 7-ketocholesterol) is an oxysterol of continuing interest in biology and medicine. In the present study, we have prepared a side-chain fluorinated analog, 3 beta-hydroxy-25,26,26,26,27,27,27-heptafluorocholest-5-en-7-one (VI), with the anticipation that the F7 substitution would block major metabolism of the 7-ketosterol, and thereby enhance its potential in vivo effects on serum cholesterol levels and other parameters. Chromium trioxide/dimethyl pyrazole oxidation of the acetate derivative of the previously described 25,26,26,26,27,27,27-heptafluorocholest-5-en-3 beta-ol (Swaminathan et al., 1993. J. Lipid Res. 34, 1805-1823) followed by mild alkaline hydrolysis gave VI. The effects of VI on 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity in Chinese hamster ovary (CHO-K1) cells, on acyl coenzyme A-cholesterol acyltransferase (ACAT) activity in rat jejunal microsomes, and on serum cholesterol levels and other parameters in male Sprague-Dawley rats were determined and compared with those obtained with I and with another alpha, beta-unsaturated ketosterol, i.e. 3 beta-hydroxy-5 alpha-cholest-8(14)-en-15-one (II). I and VI showed essentially the same potency, considerably less than that of II, in lowering the levels of HMG-CoA reductase activity in CHO-K1 cells. Whereas addition of II to rat jejunal microsomes inhibited ACAT activity (IC50 approximately 3 microM), I and VI had no effect under the conditions studied (from 1 to 16 microM). Dietary administration of I, at levels of 0.1 and 0.15%, had no effect on food consumption, gain in body weight, or serum cholesterol levels. At 0.2%, I caused a modest decrease in body weight gain and a slight decrease in serum cholesterol levels (relative to ad libitum but not pair-fed control animals). The F7-7-ketosterol VI, at 0.26% in diet (the molar equivalent of 0.2% I), had no effect on food consumption, body weight, or serum cholesterol levels. Administration of I (0.1, 0.15 or 0.2% in diet) caused increases in the weight of small intestine. In contrast, no effect of VI (0.26% in diet) on small intestinal weight was observed.
Subject(s)
Cholesterol/analogs & derivatives , Cholesterol/blood , Hydroxymethylglutaryl CoA Reductases/metabolism , Jejunum/drug effects , Sterol O-Acyltransferase/metabolism , Animals , Anticholesteremic Agents/chemical synthesis , Anticholesteremic Agents/chemistry , Anticholesteremic Agents/pharmacology , CHO Cells , Cholesterol/chemical synthesis , Cholesterol/chemistry , Cholesterol/pharmacology , Cricetinae , Cricetulus , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Feeding Behavior/drug effects , Jejunum/enzymology , Magnetic Resonance Spectroscopy , Male , Microsomes/drug effects , Microsomes/enzymology , Molecular Structure , Organ Size/drug effects , Rats , Rats, Sprague-DawleyABSTRACT
Under low-iron conditions, Escherichia coli synthesizes the siderophore enterobactin. When compared to wild-type cells grown in iron sufficient medium, cells grown under iron limitation, in the absence of tyrosine and phenylalanine or the presence of both, increased catechol production (a measure of enterobactin and its degradation product 2,3-dihydroxybenzoic acid) 5- to 9-fold while cells supplemented with tyrosine alone produced a 10- to 20-fold increase. Mutations in fur, tyrA, pheA, or pheU generally resulted in increased enterobactin production, while a tyrR mutant was unaffected by combinations of tyrosine and phenylalanine.
